Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Merck KGaA Submits Application For Cladribine Tablets As Multiple Sclerosis Therapy In Europe
Merck KGaA announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, Merck"s proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis (MS). Cladribine Tablets could become the first orally administered disease-modifying therapy available for patients with MS, as all disease-modifying therapies currently approved for the treatment of MS are injectable.
pharmacy online
ChIP-Seq, Drosophila Targeted Mutagenesis Featured In Cold Spring Harbor Protocols
High-throughput whole-genome analysis is becoming a standard laboratory approach for investigating cellular processes. Next-generation sequencing is replacing microarrays as the technique of choice for genome-scale analysis, because it offers advantages in both sensitivity and scale. The June issue of Cold Spring Harbor Protocols features "Native Chromatin Preparation and Illumina/Solexa Library Construction" from Keji Zhao and colleagues at the National Heart, Lung and Blood Institute. The article describes sample preparation for sequencing of chromatin-immunoprecipitated DNA (ChIP-Seq) to analyze histone modification patterns using native chromatin and the Solexa/Illumina Genome Analyzer. Step-by-step instructions are given for purification of human CD4+ T cells from lymphocytes and chromatin fragmentation using micrococcal nuclease (MNase) digestion, followed by chromatin immunoprecipitation (ChIP) and construction of a library for sequencing. The article is freely available on the website for Cold Spring Harbor Protocols (http://cshprotocols.cshlp.org/cgi/content/full/2009/6/pdb.prot5237).
News of the day
Discovery Of Active Genes In The Developing Mammal Brain
A study by scientists at Penn State provides new information about the genes that are involved in a mammal"s early brain development, including those that contribute to neurological disorders. The study is the first to use high-throughput sequencing to uncover active genes in developing brains, and it is likely the best evidence thus far for the activity in the brain of such a large number of genes. The research results one day could lead to the development of drugs or gene therapies that treat neurological disorders such as autism and mental retardation. The research, which was led by Distinguished Professor of Biology Hong Ma and Associate Professor of Biology Gong Chen, will be published online in the Early Edition of the Proceedings of the National Academy of Sciences sometime during the week of 13 July 2009.
Nutrition

UCLA Study Discovers Enzyme That Controls 'Bad' Cholesterol

BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" often linked to medical problems like heart disease and clogged arteries. Cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells" production of the receptor. FINDINGS: Using a mouse model, UCLA scientists discovered a new mechanism that controls cells" production of LDL receptor. The team identified an enzyme called Idol that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. In blocking Idol"s activity, the researchers triggered cells to make more receptor and absorb more cholesterol from the body. "We only know of three pathways that regulate the LDL receptor. The first two are already targeted by existing drugs," explained Dr. Peter Tontonoz, professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and an investigator at the Howard Hughes Medical Institute. "Idol is the first mechanism discovered in several years that may lead to a new medication designed to control cholesterol levels." IMPACT: The findings suggest that development of a drug that interferes with Idol"s activity could influence cholesterol metabolism and lower levels of bad cholesterol. Doctors could prescribe the new medication in conjunction with statin drugs, which also cut cholesterol levels by targeting a different enzyme linked to the LDL receptor. This could benefit patients that cannot tolerate statin-related side effects. AUTHORS: Tontonoz collaborated with Noam Zelcer, Cynthia Hong and Rima Boyadjian. The research was funded by the Howard Hughes Medical Institute and the National Heart, Lung and Blood Institute. Tontonoz and Zelcer have filed a patent related to the research findings. JOURNAL: The research appears in the June 11 online edition of the journal Science. Elaine Schmidt University of California - Los Angeles


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009